Everen Group Appoints Robert Foskey as President & CEO
The Everen Group, a group of leading energy insurance companies, is pleased to announce the appointment of Robert Foskey as the new President & Chief Executive Officer, effective August 5, 2024. Mr. Foskey brings a wealth of experience and a proven track record of success with the Everen Group and is set to lead the company into its next phase of growth and innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240806098310/en/
Robert Foskey Appointed President & CEO of Everen Group (Photo: Business Wire)
Over the past 17 years with the Everen Group, Mr. Foskey has demonstrated exceptional leadership and strategic vision, in his capacity as the Group Chief Actuary for 15 years and most recently as the Chief Operating Officer of Everen Limited. He has overseen key operational improvements and driven significant growth. Mr. Foskey has a deep understanding of the Group’s mission and values, making him the ideal choice for the role of CEO.
Mr. Foskey’s selection is the culmination of a robust, year-long leadership succession search process led by the Board. “We are extremely pleased to appoint Rob as Group CEO,” said John Weisner, Chair of the Board of Everen Limited. “His contributions as Chief Actuary and COO have been invaluable, and the Board is confident he will continue to propel the Everen Group forward with the same dedication and inspiration. The Board would also like to thank Bertil Olsson for his contributions to the Everen Group as CEO over the past nine years.”
John Talarico, Chair of the Board of Everen Specialty Ltd., added, “The Board unanimously agree that Rob is the ideal leader for the Everen Group. His in-depth knowledge of our operations and commitment to our organization will ensure a seamless transition and continued success.”
Commenting on his appointment, Mr. Foskey said, “I am honored and excited to take on the role of Group CEO. It has been a privilege to be a part of the Everen Group and to lead Everen Limited as COO. I want to thank the Board for its confidence as I step into this role. I look forward to working with our talented leadership team and employees as we continue to innovate and deliver consistent value to our shareholders and customers and advance the Group’s position as leaders in the global insurance industry. I am committed to fulfilling our mission and values and enhancing our culture through teamwork, collaboration and transparency.”
About Everen Group:
The Everen Group includes two distinct operating companies providing complementary products: Everen and Everen Specialty. Everen is the largest energy insurance mutual company in the world, operating for over 50 years and acting as a pure mutual owned by its member shareholders. Its underwriting is 100% supported by its own balance sheet with no third party capital and it offers up to $450 million of per occurrence limits. Everen Specialty is an industry owned commercial (re)insurer offering property and casualty insurance and reinsurance for members and non-members. Everen Specialty also have a subsidiary, OCIL Specialty, Ltd (OSL), writing U.S. surplus lines business through OSL Insurance Services (OISI), a managing general agent based in Houston, Texas.
For further information about the companies, please visit Everen.bm and EverenSpecialty.bm.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806098310/en/
Contacts
For inquiries regarding this press release, please contact Karyn Peixoto, VP,
Human Resources & Administration on hr@everengroup.bm
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces Publication of Phase 3 PROMIS I and II Study Results in The Lancet Respiratory Medicine Showing Efficacy Results of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis Colonized with P. aeruginosa13.9.2024 12:00:00 EEST | Press release
Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people’s health and the quality of patients’ lives, today announced the online publication of its Phase 3 PROMIS-I and PROMIS-II studies in The Lancet Respiratory Medicinejournal. The PROMIS studies assessed the efficacy and safety of inhaled colistimethate sodium administered via the I-neb® Adaptive Aerosol Delivery System (“CMS I-neb”) as a treatment to reduce the frequency of pulmonary exacerbations in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) chronically colonized with P. aeruginosa over 12 months, compared to placebo. “The publication of these pivotal data in The Lancet Respiratory Medicine represents an important milestone in our commitment to developing innovative therapies for patients with severe respiratory diseases,” said Paola Castellani, Chief Medical Officer and R&D Head at Zambon. “For patients with NCFB, a condition with no approved treatment options, the results
Intelsat Signs Hybrid Media Deal Distributing Hearst Networks EMEA Content13.9.2024 10:00:00 EEST | Press release
Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks, successfully launched a hybrid television content distribution service to deliver Hearst Networks EMEA (formerly known as A+E Networks EMEA) channels to hundreds of points across Europe thanks to its seamless satellite-terrestrial connection. “Growing global media customers like Hearst Networks EMEA want to work with a single operator that can provide seamless connections from satellite to ground-based Internet Protocol distribution networks,” said Rhys Morgan, regional vice president, EMEA, Media and Networks. “Intelsat has visibility across the full distribution network, even when it spans multiple technologies and can enable customers to reach more end users.” In order to reach a wide group of viewers, content providers typically use multiple distribution mediums such as direct-to-home (DTH), cable and IPTV. Hearst Networks EMEA needed to maximize the reach of its flagship channels, The H
NATO Support and Procurement Agency Contracts SES’s O3b mPOWER for Secure Communications Services13.9.2024 09:30:00 EEST | Press release
The NATO Support and Procurement Agency (NSPA) has awarded SES a contract to deliver secure high-performance low-latency satellite services via its medium earth orbit (MEO) constellation, enabling global missions for NATO member government organisations, agencies and military. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910404747/en/ NATO Support and Procurement Agency Contracts SES’s O3b mPOWER for Secure Communications Services (Photo: Business Wire) The MEO Global Services (MGS) award represents a three-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract valued at USD 200M, with two one-year options. This is the first award under the Global Commercially Contracted Satellite Communications Support Partnership (GCC SATCOM SP) established by the U.S. and Luxembourg under the auspices of NSPA in 2022, opening a new era of space cooperation within NATO. The MGS will be available to all NATO countries, including
SamanTree Medical Achieves FDA Clearance for Histolog® Scanner, Ushering in a New Era of Tissue Imaging in the U.S.13.9.2024 09:00:00 EEST | Press release
SamanTree Medical, a leader in innovative surgical imaging solutions, today announced that it has received FDA 510(k) clearance of its Histolog® Scanner for imaging of the internal microstructure of tissues including, but not limited to, the identification of cells, vessels and their organization or architecture. This groundbreaking Swiss made device is designed to provide real-time, highresolution imaging of fresh tissue surfaces, offering surgeons and pathologists this information for excised tissue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240912995435/en/ The Histolog Scanner in use for rapid visualization of fresh tissue microstructures. (Photo: SamanTree Medical) The Histolog® Scanner enables real-time, ultra-fast confocal microscopy, allowing for the immediate imaging of resected tissues. This advancement aims to enable physicians to improve their efficiency. “We are thrilled to introduce the Histolog® Scanner t
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types13.9.2024 09:00:00 EEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III. Other presentations will include findings from studies evaluating Guardant360® for therapy selection in advanced breast cancer and other solid tumors, and the Guardant Infinity™ platform for response monitoring in advanced non-small cell lung cancer (NSCLC). “Our latest data featured at ESMO further highlight the value of Guardant’s technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom